Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Dabocemagene Autoficel (D-Fi; FCX-007; Genetically Modified Autologous Human Dermal Fibroblasts) for the Treatment of Wounds Due to Dystropic Epidermolysis Bullosa

NCT06892639 is registered in ClinicalTrials.gov with Castle Creek Biosciences, LLC. as lead sponsor.

NCT NCT06892639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06892639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Dabocemagene Autoficel (D-Fi; FCX-007; Genetically Modified Autologous Human Dermal Fibroblasts) for the Treatment of Wounds Due to Dystropic Epidermolysis Bullosa
Lead sponsor
Castle Creek Biosciences, LLC.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 27, 2025
Completion date
February 28, 2042
Enrollment
32 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

dystrophic epidermolysis bullosa